C4 Therapeutics (CCCC) EBITDA (2019 - 2026)
C4 Therapeutics (CCCC) posted quarterly EBITDA of -$27.8 million for Q1 2026, up 4.73% year-over-year from -$26.5 million in Q1 2025, and down 20.05% quarter-over-quarter from -$23.1 million in Q4 2025.
C4 Therapeutics (CCCC) EBITDA (2019 - 2026) Analysis & Trends
C4 Therapeutics' EBITDA history runs 8 years deep, the most recent figure standing at -$27.8 million for Q1 2026.
- In Q1 2026, EBITDA rose 4.73% year-over-year to -$27.8 million; the TTM figure through Mar 2026 stood at -$113.8 million (up 2.33% YoY), while the FY2025 annual figure was -$115.2 million, up 3.67% from the prior year.
- EBITDA for Q1 2026 stood at -$27.8 million, down from -$23.1 million in the prior quarter.
- The five-year high for EBITDA was -$21.4 million in Q2 2024, with the low at -$38.3 million in Q4 2022.
- The 5-year median for EBITDA is -$31.4 million (2022), against an average of -$31.2 million.
- The sharpest annual moves came in 2022 and 2024: EBITDA tumbled 151.02% in 2022, then jumped 42.92% in 2024.
- C4 Therapeutics' EBITDA stood at -$38.3 million in 2022, then gained by 2.26% to -$37.4 million in 2023, then retreated by 0.75% to -$37.7 million in 2024, then surged by 38.62% to -$23.1 million in 2025, then declined by 20.05% to -$27.8 million in 2026.
- Business Quant data shows CCCC's EBITDA at -$27.8 million in Q1 2026, -$23.1 million in Q4 2025, and -$34.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | C4 Therapeutics | 521.12 Mn | 267.46 Mn | - | -26.42 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -26.42 Mn |
| Mar 31, 2026 | -27.79 Mn |
| Dec 31, 2025 | -23.15 Mn |
| Sep 30, 2025 | -34.41 Mn |
| Jun 30, 2025 | -28.50 Mn |
| Mar 31, 2025 | -29.16 Mn |
| Dec 31, 2024 | -37.71 Mn |
| Sep 30, 2024 | -28.24 Mn |
| Jun 30, 2024 | -21.44 Mn |
| Mar 31, 2024 | -32.22 Mn |
| Dec 31, 2023 | -37.43 Mn |
| Sep 30, 2023 | -27.81 Mn |
| Jun 30, 2023 | -37.57 Mn |
| Mar 31, 2023 | -36.23 Mn |
| Dec 31, 2022 | -38.29 Mn |
| Sep 30, 2022 | -32.49 Mn |
| Jun 30, 2022 | -27.38 Mn |
| Mar 31, 2022 | -31.37 Mn |
| Dec 31, 2021 | -15.26 Mn |
| Sep 30, 2021 | -24.25 Mn |